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PSaving Athletes’ Lives
A Reason to Find Common Ground?
Pamela S. Douglas, MD, MACC
Durham, North Carolina
Although both U.S. and European guidelines recommend screening athletes for suspected heart disease before
participation in competitive sport, they disagree on which findings are associated with increased risk as well as
those athletes whose activities should be restricted. Recent Italian data suggest that screening programs can
save lives, but few countries have fully adopted such practices. It is time to develop an international consensus
on who should receive pre-participation screening, who should perform the screening, what tests the screening
should consist of, and what criteria should be used to restrict participation. (J Am Coll Cardiol 2008;52:
1997–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.069o
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lxtraordinary physical fitness does not confer immunity
o the tragedy of sudden cardiac death (SCD). Although
he combination of some forms of heart disease with
xercise can be lethal and there is universal agreement
bout the need to screen athletes for suspected heart
isease before participation in competitive sport, recom-
endations as to how best to accomplish this differ from
ne side of the Atlantic to the other (1,2), and actual
ractice is even more variable. Disagreement also exists on
hich findings are associated with increased risk as well as
he guidelines for who should not participate in competitive
port (3–5). Perhaps not surprisingly, given this lack of
onsensus, much of what we know is based on expert
pinion rather than substantive prospective research, and
ew cardiologists have extensive experience with athletes at risk.
In this issue of the Journal, Corrado et al. (6) provide
etails on one such extensive experience through a retro-
pective observational analysis of a regional Italian pre-
articipation screening program. Their data show a remark-
ble drop in the rate of SCD in athletes after program
nitiation, from approximately 4/100,000 to 1/100,000,
hereas the rate of athlete disqualification due to suspected
ardiomyopathy doubled. The SCD rate for athletes is now
he same as the general Italian population, but it is also the
ame as the rate in the athletic population in the U.S., which
as less rigorous pre-participation screening programs. Al-
hough some of these data have been previously presented
7,8), the present article emphasizes the implications of this
nique program, which have not been universally accepted,
nd the lessons we might learn from them. It is a timely
essage in this Olympic year.m
rom Duke University, Durham, North Carolina.
Manuscript received June 25, 2008; accepted July 1, 2008.One of the first lessons is to more clearly define the goals
f screening. Corrado et al. (6) emphasize that they seek to
dentify a population of individuals who might be at
levated risk rather than single individuals with heart
isease. This subtle shift in focus leads to a higher rate of
ubsequent testing (usually echocardiography) than has been
eported in at least 1 American series (9% vs. 3%) (9) and
itigates the impact of any lack of specificity in the initial
creening. However, the diseases responsible for causing
CDmight differ in this region with its higher prevalence of
ight ventricular cardiomyopathies and higher death rate
resent before beginning the screening program, possibly
ffecting these results and their “translatability” to other
ountries. Such issues are difficult to resolve; the underlying
revalence of disease is still in dispute, even for well-studied
ntities such as hypertrophic cardiomyopathy (10).
Additional lessons can be learned regarding the Italians’
creening methodology and personnel (6). Most important
f these is the use of electrocardiograms (ECGs) as part of
heir screening program in addition to a cardiac history and
hysical, a strategy endorsed by the European Society of
ardiology but not the American Heart Association guide-
ines (1,2) and that remains controversial in the U.S.
11,12). In spite of this, screening methods have become
ignificantly more rigorous in the U.S. over the past decade,
nd although still not requiring an ECG, more states now
equire screening, and the mandated questionnaires more
ompletely explore cardiovascular risk (13). The Italian
creeners are sports physicians, with 4 years of post-
raduate training in sports medicine and cardiology,
ncluding the recognition of ECG abnormalities in ath-
etes, and all were in sports medicine practice full time. In
ontrast, in the U.S., over time screeners are becoming
ess likely to be physicians or even trained in sports
edicine (13).
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Saving Athletes’ Lives: A Reason to Find Common Ground? December 9, 2008:1997–9In addition to the size of ath-
letic programs in the U.S. and
the limited availability of trained
sports medicine physicians, the
costs of implementing a similar
program might be prohibitive. In
Italy, screening costs about €30/
thlete and, along with any needed subsequent testing, is at
east partially supported by the National Health System.
urthermore, a favorable environment regarding possible
iability of the screening program for missed diagnoses is
lso present (6). Other incompletely resolved methodologic
uestions include the competitive level of athletes who
hould be screened, the frequency of repeat screening, and
he criteria used to determine the need for additional
esting. Every screening program must explicitly or implic-
tly wrestle with these issues, and the experience of Corrado
t al. (6) can provide some guidance in the absence of clear
uidelines.
Another lesson is related to the link between the effec-
iveness of screening and reduced death, which can only be
hrough the actions taken in response to screening results.
nce again European and American recommendations
rom an American College of Cardiology Bethesda Confer-
nce differ, as nicely dissected by Pelliccia et al. (3–5,14).
lthough both documents advocate restricting activity in
thletes deemed to be at risk, definitions of who is at risk
ary significantly, and the level of exercise limitation rec-
mmended is not uniform. The European guidelines are
ore restrictive in many cases, tilting the balance toward
roscription of activity rather than individual freedom to
ursue sport. The result of this recommendation is demon-
trated in practice by the high exclusion rate in the Italian
rograms of 2% of those screened, despite only 0.2% having
potentially lethal” conditions (7). The “pursuit of happi-
ess” is a characteristically American concept, and the
xistence of a U.S. legal precedent that allows athletes to
hoose to participate despite elevated risk is relevant to the
ontent of both screening and participation guidelines and
he ability to implement them in practice.
In addition to such cultural differences, the European but
ot the American guidelines advise against participation for
enotype-positive, phenotype-negative athletes with hyper-
rophic cardiomyopathy, Brugada syndrome, long-QT syn-
rome, and Marfan syndrome. Extrapolation of these rec-
mmendations suggests that consideration should be given
o genotyping asymptomatic athletes for mutations known
o be associated with these diseases as part of pre-
articipation screening. The implications are staggering in
erms of the required expense and expertise (not coinciden-
ally, these same objections are raised to support screening
ithout using ECGs) and in terms of ethics: could the
pportunity to participate in sport be reasonably withheld
or a positive genotype with no other manifestations of
isease? Furthermore, if one were to accept this hypothetical
Abbreviations
and Acronyms
ECG  electrocardiogram
SCD  sudden cardiac
deathpproach, the possibility of prejudice based on genetic anformation is substantial. Perhaps fortuitously, Van Driest
t al. (15) found that only 30% to 61% of individuals with
henotypic hypertrophic cardiomyopathy had previously
eported and therefore detectable mutations, suggesting that
he yield of genetic screening would be low at present. Even
f genotyping were performed only in those who have
ositive clinical features (i.e., a pre-clinical phenotype or
amily history), it is unclear how the extra expense of testing
or genetic risk and the uncertainty with regard to acting
pon its results would be handled, especially in light of the
ack of agreement on the proper use of a time-honored and
nexpensive test such as an ECG. However, it is only a
atter of time until advances in genetic science and tech-
ologies make this approach more accurate and perhaps
ven feasible. Until such questions can be answered, one
ust assume that the European guidelines are to be fol-
owed with a “don’t ask, don’t tell” approach, whereby
enetic testing is only performed once other parameters
ndicate the possible presence of disease.
Whereas issues such as genetic testing will continue to
volve, it is critical to ask what level of evidence would be
equired to harmonize current approaches to pre-participation
creening. At present, although most countries in Europe
ave slightly different policies, most do require an ECG as
art of pre-participation testing. In the U.S. a growing
onsumer movement is increasingly bypassing the ECG in
avor of screening with an echocardiogram (16). Although
he echocardiogram is arguably more sensitive and certainly
ore specific than the ECG for diagnosis of hypertrophic
ardiomyopathy, its accuracy for other abnormalities causing
ardiac arrest, such as the “channelopathies,” is arguably
orse and certainly untested. In the likely continued ab-
ence of randomized trials testing alternative screening
trategies, despite calls for such research (11,12), are the
bservational results of Corrado et al. (6) powerful enough
o alter U.S. guidelines and, most importantly, screening
ractices? If not, what level of evidence would be required,
nd how can we develop it? Similar questions revolve
round testing the validity of differing participation recom-
endations where even less evidence is available.
Few things are more universally mourned than the
udden death of an athlete. Yet our scientific and clinical
ommunity has responded in a fragmented manner, which
an leave the sports community confused as to how to
nsure the health of athletes, clinicians uncertain how to
are for an individual patient, and parents of young athletes
n fear for their offspring’s health. To develop a single
nternational consensus, experts would have to reach agree-
ent on the cardiovascular risks of competitive athletics and
he recommended procedures and personnel involved in
creening for possible disease, and adopt similar policies
estricting participation in those at risk. Perhaps this vision
s too ambitious, and we can only hope that physicians and
thers can learn from the Italian “experiment.” But don’t our
thletes deserve more than this?
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